Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MyRisk Akynzeo study in high-risk patients receiving moderately emetogenic chemotherapy
2019-004686-41Phase 4Unknown
- Sponsor
- Helsinn
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of palonosetron in chemotherapy-induced nausea and vomiting (CINV) and cancer (2 arms), sponsored by Helsinn. Status: unknown.
02
Drugs
palonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)cancer
Beyond the preview
Go deeper on 2019-004686-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004686-41.